NDAORALTABLETPriority Review
Approved
Nov 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Clinical Trials (5)
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Started May 2026
16 enrolled
Small Cell Lung Cancer ( SCLC )Transformed Small Cell Lung Cancer
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
Started Mar 2026
60 enrolled
Lung Cancer
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
Started Feb 2026
60 enrolled
Lung Non-Small Cell Carcinoma
Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.
Started Jan 2026
100 enrolled
Non-small Cell Lung Cancer
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
Started Sep 2025
250 enrolled
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
Loss of Exclusivity
LOE Date
Nov 26, 2042
203 months away
Patent Expiry
Nov 26, 2042
Exclusivity Expiry
Dec 18, 2027